Short answer
Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Enliven Therapeutics’ financial results for the quarter ended September 30, 2026.
Enliven Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Enliven Therapeutics’ financial results for the quarter ended September 30, 2026
- Detailed financial figures and management commentary are contained in Exhibit 99.1
- Results update investors on cash position, operating expenses and development funding needs
Item EX-99.1 · Exhibit EX-99.1
- FDA alignment on ENABLE-2 final design reduces regulatory uncertainty ahead of pivotal Phase 3 launch before year-end 2026
- Planned trial: approximately 450 patients, relcobatinib 80 mg versus investigator-selected second-generation TKI
- $884.4M cash, equivalents and marketable securities, supporting projected runway into 2030 and limiting near-term financing risk
- R&D expense rose to $28.0M from $18.2M, reflecting accelerated development investment
- Net loss widened to $27.7M from $20.1M, signaling increasing cash-burn pressure despite strong liquidity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Enliven Therapeutics, Inc. 8-K filings
Get the next ELVN 8-K as it lands
Follow ELVN for push alerts, or ask the research agent what this filing means.